Boardroom Battle Erupts at Staar Surgical Ahead of Crucial Vote

A dramatic power struggle is unfolding at ophthalmic device maker Staar Surgical, casting severe doubt over its pending acquisition by industry giant Alcon. The company’s largest shareholder, activist investor Broadwood Partners, has launched a direct assault on the leadership team by demanding a special meeting to oust three key directors.

Activist Investor Moves to Oust Leadership

Broadwood Partners, which controls a significant 30.2% stake in Staar Surgical, is seeking the immediate removal of Board Chair Elizabeth Yeu, Chief Executive Stephen Farrell, and Compensation Committee Chair Arthur Butcher. The investor has sharply criticized the company’s strategic direction, labeling the sales process as “flawed” and arguing that the proposed transaction with Alcon severely undervalues the business.

Concerns over potential conflicts of interest are central to the activist’s campaign. Broadwood has highlighted a contingent payment of $24 million earmarked for CEO Stephen Farrell should the Alcon deal close. The investor has also raised questions about undisclosed relationships between Board Chair Elizabeth Yeu and Alcon.

Shareholder Base Splits as Vote Nears

The escalating turmoil comes just weeks before a critical shareholder vote on the Alcon acquisition, which has already been postponed three times. This uncertainty is causing a clear divergence in investment strategy among major stakeholders.

In a strong show of conviction, Broadwood Partners bolstered its position on November 21 by purchasing an additional 797,486 shares for approximately $22.2 million. Conversely, another significant investor has headed for the exit. Palo Alto Investors liquidated its entire holding during the third quarter, selling 791,879 shares. This divestment of a position previously worth over $13 million signals a stark lack of confidence in either the deal’s prospects or the company’s stability amid the current upheaval.

Should investors sell immediately? Or is it worth buying Staar Surgical?

Solid Fundamentals Amidst Takeover Turmoil

The boardroom clash is set against a deadline of December 19, 2025, the date currently scheduled for the shareholder vote on the Alcon transaction. With nearly one-third of voting rights opposed, securing the necessary majority for the sale has become a formidable mathematical challenge.

Paradoxically, Staar Surgical’s standalone financial performance remains robust, lending credence to Broadwood’s argument for maintaining independence. The company’s most recent quarterly results showed revenue growth of 6.9%, a strong gross margin of 82.2%, and a net profit of $8.9 million.

Heightened Volatility Expected Through December

Investors should brace for significant share price fluctuations leading up to the December 19 decision. The market is now weighing two distinct scenarios: the collapse of the Alcon deal, which could trigger an initial sell-off by arbitrage traders, or a successful boardroom coup that would chart a new independent strategic course.

Trading around $26 per share, Staar Surgical’s equity has become the focal point of this corporate control contest. Market observers note that if Broadwood succeeds in convening its special meeting before the scheduled vote, the Alcon acquisition is almost certainly doomed to fail.